# BridgeBio Pharma, Inc. (BBIO) MD&A by fiscal year

Verbatim Item 7 Management's Discussion and Analysis sections from BridgeBio Pharma, Inc.'s 10-K filings, one page per fiscal year. Extracted from SEC filings with the same bounded parser for every year. Filer text, not grepcent analysis or investment advice.

- [FY 2025 MD&A](/company/BBIO/mda/fy2025/): filed 2026-02-24; accession 0001743881-26-000009 (https://www.sec.gov/Archives/edgar/data/1743881/000174388126000009/bbio-20251231.htm); latest 10-K
- [FY 2024 MD&A](/company/BBIO/mda/fy2024/): filed 2025-02-20; accession 0000950170-25-024119 (https://www.sec.gov/Archives/edgar/data/1743881/000095017025024119/bbio-20241231.htm)
- [FY 2023 MD&A](/company/BBIO/mda/fy2023/): filed 2024-02-22; accession 0000950170-24-018811 (https://www.sec.gov/Archives/edgar/data/1743881/000095017024018811/bbio-20231231.htm)
- [FY 2022 MD&A](/company/BBIO/mda/fy2022/): filed 2023-02-23; accession 0000950170-23-004145 (https://www.sec.gov/Archives/edgar/data/1743881/000095017023004145/bbio-20221231.htm)
- [FY 2021 MD&A](/company/BBIO/mda/fy2021/): filed 2022-02-25; accession 0000950170-22-002030 (https://www.sec.gov/Archives/edgar/data/1743881/000095017022002030/bbio-20211231.htm)

Back to /company/BBIO/